Cellecta, Inc. Announces Upcoming Presentations at the American Association for Cancer Research 2017 Annual Meeting

Presentations on Cellecta technology developments in CRISPR screening technologies and the Driver-Map™Targeted RNA Expression Profiling Solution

News provided by

Cellecta, Inc.

Mar 15, 2017, 08:35 ET

MOUNTAIN VIEW, Calif., March 15, 2017 /PRNewswire/ -- Cellecta, Inc. today announced that it will deliver three scientific presentations at the upcoming American Association for Cancer Research (AACR) 2017 Annual Meeting, which will be take place April 1-5, 2017 at the Walter E. Washington Convention Center in Washington, D.C. Cellecta researchers will present unpublished data on technology developments in genetic screens in human cancer cell lines using CRISPR-knockout, CRISPRi and CRISPRa; as well as new data on applications of the Driver-Map targeted RNA expression solution for profiling immunity biomarkers and cellular composition analysis.

Details of the presentations are as follows:

Poster Abstract 403/ Poster 3: CRISPR/Cas9 genome-wide sgRNA libraries for loss-of-function and gain-of-function genetic screens
Session: Genomic Screening for Cancer Dependencies and Drug Response
Date and Time: Sunday, April 2, 2017, 1:00 - 5:00 p.m. Eastern Time
Location: Convention Center, Halls A-C, Poster Section 17

Spotlight Theatre Presentation: Driver-Map™ Assay: Gene Expression profiling of protein-coding genes for tumor microenvironment analysis and biomarker discovery
Date and Time: Tuesday, April 4, 2017, 10:00 – 11:00 a.m. Eastern Time
Location: Convention Center, Spotlight Theatre B – Hall A

Poster Abstract 4652/ Poster 13: Profiling of immunity biomarkers in whole blood
Session: Diagnostic Biomarkers
Date and Time: Tuesday, April 4, 2017, 1:00 - 5:00 p.m. Eastern Time
Location: Convention Center, Halls A-C, Poster Section 28

About Cellecta:

Cellecta, Inc., a trusted provider of genomic products and services, is an industry leader in RNAi and CRISPR technologies for the discovery and characterization of novel therapeutic targets, and genetic profiling for biomarker discovery. Numerous scientific papers have been published citing Cellecta's functional genomics portfolio offering gene knockout and knockdown screens, custom and genome-wide RNAi and CRISPR libraries, cell engineering, RNAi and CRISPR construct services, and mutation and expression profiling of disease samples.

Cellecta, Inc. is headquartered in Mountain View, California. Further information about the company and its functional genomic products and services may be found online at www.cellecta.com

Cellecta, Inc.

Paul Diehl, 650-938-4050
[email protected]

Media: Ruth Mercado, 650-938-4080
[email protected]

SOURCE Cellecta, Inc.